Taiwan Scientists Find Gene Key To Gleevec Resistance
This article was originally published in PharmAsia News
Taiwanese researchers report discovery of a gene that could lead to new drugs to treat leukemia. The scientists looked specifically at alternatives for treating chronic myelogenous leukemia, currently treated with the Novartis drug Gleevec (imatinib mesylate) to extend lives as long as 15 years. Many patients become resistant to Gleevec, the researchers said, because of the drug's suppression of a certain gene, suggesting another drug, perhaps an existing and cheaper one, could be used to allow the gene to do its work. (Click here for more
You may also be interested in...
Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.
A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall.
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.